Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Recommendation of “Buy” by Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned a consensus recommendation of “Buy” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a buy rating and three have given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $16.5556.

A number of research analysts recently weighed in on IVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. HC Wainwright set a $24.00 price target on Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. Truist Financial started coverage on Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target for the company. Finally, Barclays started coverage on shares of Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price target on the stock.

Inventiva Price Performance

NASDAQ:IVA opened at $5.37 on Monday. Inventiva has a one year low of $2.85 and a one year high of $7.98. The company’s 50-day simple moving average is $5.74 and its 200 day simple moving average is $5.34.

Inventiva (NASDAQ:IVA) last announced its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $0.01 million for the quarter. On average, equities research analysts anticipate that Inventiva will post -0.79 EPS for the current year.

Institutional Investors Weigh In On Inventiva

A number of institutional investors have recently made changes to their positions in IVA. Paradigm Biocapital Advisors LP bought a new stake in shares of Inventiva during the fourth quarter valued at approximately $18,600,000. ADAR1 Capital Management LLC purchased a new stake in Inventiva during the 4th quarter valued at $12,601,000. UBS Group AG boosted its stake in Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. SymBiosis Capital Partners LLC bought a new stake in shares of Inventiva in the 4th quarter worth $12,090,000. Finally, Millennium Management LLC raised its stake in shares of Inventiva by 2,267.7% in the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock worth $12,334,000 after purchasing an additional 2,540,540 shares during the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.